TRACON gets Nasdaq delisting notice; CBDO resigns

Tracon Pharmaceuticals, Inc.

Nasdaq Hearings Panel determined to delist TCON common stock effective June 13, 2024 for noncompliance with continued listing requirements.
Trading continues on Nasdaq as of filing date; company expects to move to OTCQB Venture Market under symbol TCON.
David Lazar voluntarily resigned as Chief Business Development Officer effective June 19, 2024; no disagreement with the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Lazar

Chief Business Development Officer

Tracon Pharmaceuticals, Inc.

Effective: 2024-06-19
Filed: June 21, 2024, 7:59 PM ET

On June 19, 2024, David Lazar notified the Company that he voluntarily resigned from his position as Chief Business Development Officer of the Company, effective June 19, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Lazar resigned as Chief Business Development Officer at Tracon Pharmaceuticals, Inc..

Action: resigned
Role: Chief Business Development Officer

Exact text from the filing

On June 19, 2024, David Lazar notified the Company that he voluntarily resigned from his position as Chief Business Development Officer of the Company, effective June 19, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-076330

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.